On September 17, 2019, the combination therapy of Eisai’s LENVIMA (lenvatinib) and Merck’s KEYTRUDA (pembrolizumab) for the treatment of advanced endometrial carcinoma received simultaneous approvals by Health Canada, the U.S. Food and Drug Administration (FDA), and the Australian Therapeutic Goods Administration.
The joint decision by all three regulatory authorities was the first of its kind and a direct result of the collaborative review process under Project Orbis, a new initiative of the FDA Oncology Center of Excellence. Project Orbis provides the framework for concurrent submission and review of oncology products among international partners despite regulatory divergence, with the goal of facilitating early patient access to innovative oncology products and promoting greater uniformity in the standards of treatment.
In a news release announcing the first action under Project Orbis, the FDA indicated that other countries in addition to Canada and Australia may be involved in future collaborative reviews.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Update on biosimilars in Canada – June 2025
This article provides an update on developments in the biosimilar space in Canada—regulatory, approvals, pending submissions, litigation, and market access.Read More -
Health Canada must redetermine exemption requests for psilocybin (magic mushroom)-assisted psychotherapy training
TheraPsil, a patient advocacy organization, and 73 healthcare practitioners (HCPs) have succeeded in the Federal Court of Appeal to overturn the refusal of the Minister of Mental Health and Addictions...Read More -
2025 mid-year highlights in Canadian life sciences IP and regulatory law
In the first half of 2025, the Rx IP Update team reported on a number of developments in Canadian life sciences IP and regulatory law. Below are our top stories.Read More